What is the primary driver behind the significant revenue decline reported for the third quarter and nine months of 2003?

The primary driver for the revenue decline is the loss of market exclusivity for CLARITIN in the United States and its subsequent conversion to over-the-counter (OTC) status. This led to a substantial drop in prescription sales of CLARITIN, impacting overall sales figures.

How has the company's profitability been affected in the current period?

Profitability has been significantly impacted. The company reported a net loss of $265 million for the third quarter of 2003, a sharp reversal from a net income of $429 million in the same period of 2002. For the nine-month period, net income decreased dramatically to $90 million from $1.66 billion in the prior year.

What is the significance of the $350 million increase in litigation reserves?

The $350 million provision to increase litigation reserves is a significant non-recurring charge that adversely affected the company's net income for the quarter and nine months. This provision relates to ongoing investigations by U.S. Attorney's Offices concerning the company's marketing, sales, and clinical trial practices. Investors should monitor the resolution of these investigations as they could lead to further financial impacts.

What is the company's outlook for the remainder of 2003 and 2004, and what actions are being taken?

The company anticipates that earnings per share (EPS) in the second half of 2003 will be lower than the first half, and that 2004 EPS may also be lower than 2003. In response, Schering-Plough is implementing accelerated cost-cutting measures, including a global workforce reduction and a voluntary early retirement program. They have also significantly reduced their quarterly dividend.

MRK 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

Schering-Plough Corporation reported a significant net sales decline of 16% for the third quarter of 2003, reaching $2.04 billion, and a 17% decrease for the nine-month period, totaling $6.45 billion. This decline was primarily driven by the loss of market exclusivity and conversion to over-the-counter (OTC) status for its key product, CLARITIN, which led to a substantial drop in prescription sales. The company also experienced a net loss of $265 million for the quarter, a sharp contrast to the $429 million net income in the prior year's quarter. For the nine months, net income fell to $90 million from $1.66 billion year-over-year. Management's discussion highlights increased R&D spending, a rise in cost of sales as a percentage of sales due to product mix and compliance efforts, and a substantial $350 million provision for increased litigation reserves. The company is undergoing significant cost-cutting measures and has reduced its quarterly dividend. Despite these challenges, international sales showed growth, and new products like ZETIA are beginning to contribute. However, the company warned of potentially lower earnings in the second half of 2003 and into 2004.

Key Highlights

1Significant year-over-year decline in net sales for both the third quarter (-16%) and nine months (-17%), primarily due to the loss of CLARITIN exclusivity and its transition to OTC status.
2Reported a net loss of $265 million for the third quarter, compared to a net income of $429 million in the prior year's quarter.
3Nine-month net income significantly decreased to $90 million from $1.66 billion in the same period of 2002.
4A substantial $350 million provision was recorded to increase litigation reserves, impacting the 'Other (income) expense, net' line item.
5Research and Development (R&D) expenses increased by 13% in the third quarter and 12% for the nine months, reflecting continued investment in drug development.
6International sales demonstrated resilience, growing 5% in the third quarter and 8% for the nine-month period, bolstered by favorable foreign exchange rates.
7The company is implementing cost-cutting measures, including a global workforce reduction, and has reduced its quarterly dividend to 5.5 cents from 17 cents.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2003

Summary

Key Highlights

Frequently Asked Questions